Novel RAF/MEK inhibitor CH5126766/VS‐6766 has efficacy in combination with eribulin for the treatment of triple‐negative breast cancer

Various molecular‐targeting drugs have markedly improved the treatment of patients with breast cancer. As yet, therapies for triple‐negative breast cancer are mainly cytotoxic agents. To investigate the novel therapy for triple‐negative breast cancer, we herein examined the effects of a new combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Hisako, Horinaka, Mano, Sukeno, Mamiko, Morita, Mie, Yasuda, Shusuke, Nishimoto, Emi, Konishi, Eiichi, Sakai, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486178/
https://www.ncbi.nlm.nih.gov/pubmed/34288272
http://dx.doi.org/10.1111/cas.15071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486178/
https://www.ncbi.nlm.nih.gov/pubmed/34288272
http://dx.doi.org/10.1111/cas.15071

Ejemplares similares